201 related articles for article (PubMed ID: 23269286)
21. Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients.
Bloomfield D; Carlson GL; Sapre A; Tribble D; McKenney JM; Littlejohn TW; Sisk CM; Mitchel Y; Pasternak RC
Am Heart J; 2009 Feb; 157(2):352-360.e2. PubMed ID: 19185645
[TBL] [Abstract][Full Text] [Related]
22. Effects of CETP inhibition with anacetrapib on metabolism of VLDL-TG and plasma apolipoproteins C-II, C-III, and E.
Millar JS; Lassman ME; Thomas T; Ramakrishnan R; Jumes P; Dunbar RL; deGoma EM; Baer AL; Karmally W; Donovan DS; Rafeek H; Wagner JA; Holleran S; Obunike J; Liu Y; Aoujil S; Standiford T; Gutstein DE; Ginsberg HN; Rader DJ; Reyes-Soffer G
J Lipid Res; 2017 Jun; 58(6):1214-1220. PubMed ID: 28314859
[TBL] [Abstract][Full Text] [Related]
23. Safety of inhibition of cholesteryl ester transfer protein with anacetrapib: the DEFINE study.
Gotto AM; Moon JE
Expert Rev Cardiovasc Ther; 2012 Aug; 10(8):955-63. PubMed ID: 23030283
[TBL] [Abstract][Full Text] [Related]
24. Design of the DEFINE trial: determining the EFficacy and tolerability of CETP INhibition with AnacEtrapib.
Cannon CP; Dansky HM; Davidson M; Gotto AM; Brinton EA; Gould AL; Stepanavage M; Liu SX; Shah S; Rubino J; Gibbons P; Hermanowski-Vosatka A; Binkowitz B; Mitchel Y; Barter P;
Am Heart J; 2009 Oct; 158(4):513-519.e3. PubMed ID: 19781408
[TBL] [Abstract][Full Text] [Related]
25. Anacetrapib, a cholesterol ester transfer protein (CETP) inhibitor for the treatment of atherosclerosis.
Masson D
Curr Opin Investig Drugs; 2009 Sep; 10(9):980-7. PubMed ID: 19705341
[TBL] [Abstract][Full Text] [Related]
26. Deficiency of Cholesteryl Ester Transfer Protein Protects Against Atherosclerosis in Rabbits.
Zhang J; Niimi M; Yang D; Liang J; Xu J; Kimura T; Mathew AV; Guo Y; Fan Y; Zhu T; Song J; Ackermann R; Koike Y; Schwendeman A; Lai L; Pennathur S; Garcia-Barrio M; Fan J; Chen YE
Arterioscler Thromb Vasc Biol; 2017 Jun; 37(6):1068-1075. PubMed ID: 28428219
[TBL] [Abstract][Full Text] [Related]
27. In vivo effects of anacetrapib on preβ HDL: improvement in HDL remodeling without effects on cholesterol absorption.
Wang SP; Daniels E; Chen Y; Castro-Perez J; Zhou H; Akinsanya KO; Previs SF; Roddy TP; Johns DG
J Lipid Res; 2013 Oct; 54(10):2858-65. PubMed ID: 23898048
[TBL] [Abstract][Full Text] [Related]
28. Modulating cholesteryl ester transfer protein activity maintains efficient pre-β-HDL formation and increases reverse cholesterol transport.
Niesor EJ; Magg C; Ogawa N; Okamoto H; von der Mark E; Matile H; Schmid G; Clerc RG; Chaput E; Blum-Kaelin D; Huber W; Thoma R; Pflieger P; Kakutani M; Takahashi D; Dernick G; Maugeais C
J Lipid Res; 2010 Dec; 51(12):3443-54. PubMed ID: 20861162
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of lipids, drug concentration, and safety parameters following cessation of treatment with the cholesteryl ester transfer protein inhibitor anacetrapib in patients with or at high risk for coronary heart disease.
Gotto AM; Cannon CP; Li XS; Vaidya S; Kher U; Brinton EA; Davidson M; Moon JE; Shah S; Dansky HM; Mitchel Y; Barter P;
Am J Cardiol; 2014 Jan; 113(1):76-83. PubMed ID: 24188894
[TBL] [Abstract][Full Text] [Related]
30. Cholesteryl ester transfer protein (CETP) deficiency and CETP inhibitors.
Mabuchi H; Nohara A; Inazu A
Mol Cells; 2014 Nov; 37(11):777-84. PubMed ID: 25410905
[TBL] [Abstract][Full Text] [Related]
31. The apolipoprotein A-I mimetic peptide ETC-642 exhibits anti-inflammatory properties that are comparable to high density lipoproteins.
Di Bartolo BA; Nicholls SJ; Bao S; Rye KA; Heather AK; Barter PJ; Bursill C
Atherosclerosis; 2011 Aug; 217(2):395-400. PubMed ID: 21571275
[TBL] [Abstract][Full Text] [Related]
32. Investigational CETP antagonists for hyperlipidemia and atherosclerosis prevention.
Sirtori CR
Expert Opin Investig Drugs; 2011 Nov; 20(11):1543-54. PubMed ID: 21961529
[TBL] [Abstract][Full Text] [Related]
33. Anacetrapib as a potential cardioprotective strategy.
Di Bartolo BA; Nicholls SJ
Drug Des Devel Ther; 2017; 11():3497-3502. PubMed ID: 29263647
[TBL] [Abstract][Full Text] [Related]
34. Anacetrapib promotes reverse cholesterol transport and bulk cholesterol excretion in Syrian golden hamsters.
Castro-Perez J; Briand F; Gagen K; Wang SP; Chen Y; McLaren DG; Shah V; Vreeken RJ; Hankemeier T; Sulpice T; Roddy TP; Hubbard BK; Johns DG
J Lipid Res; 2011 Nov; 52(11):1965-73. PubMed ID: 21841206
[TBL] [Abstract][Full Text] [Related]
35. Lipids, safety parameters, and drug concentrations after an additional 2 years of treatment with anacetrapib in the DEFINE study.
Gotto AM; Kher U; Chatterjee MS; Liu Y; Li XS; Vaidya S; Cannon CP; Brinton EA; Moon JE; Shah S; Dansky HM; Mitchel Y; Barter P;
J Cardiovasc Pharmacol Ther; 2014 Nov; 19(6):543-9. PubMed ID: 24737712
[TBL] [Abstract][Full Text] [Related]
36. Cholesteryl ester transfer protein inhibition to reduce cardiovascular risk: Where are we now?
Barter P; Rye KA
Trends Pharmacol Sci; 2011 Dec; 32(12):694-9. PubMed ID: 22088767
[TBL] [Abstract][Full Text] [Related]
37. Chloroform extract of aged black garlic attenuates TNF-α-induced ROS generation, VCAM-1 expression, NF-κB activation and adhesiveness for monocytes in human umbilical vein endothelial cells.
Lee EN; Choi YW; Kim HK; Park JK; Kim HJ; Kim MJ; Lee HW; Kim KH; Bae SS; Kim BS; Yoon S
Phytother Res; 2011 Jan; 25(1):92-100. PubMed ID: 20623600
[TBL] [Abstract][Full Text] [Related]
38. Assessing the mechanisms of cholesteryl ester transfer protein inhibitors.
Zhang M; Lei D; Peng B; Yang M; Zhang L; Charles MA; Rye KA; Krauss RM; Johns DG; Ren G
Biochim Biophys Acta Mol Cell Biol Lipids; 2017 Dec; 1862(12):1606-1617. PubMed ID: 28911944
[TBL] [Abstract][Full Text] [Related]
39. Trials and Tribulations of CETP Inhibitors.
Tall AR; Rader DJ
Circ Res; 2018 Jan; 122(1):106-112. PubMed ID: 29018035
[TBL] [Abstract][Full Text] [Related]
40. Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease.
; Bowman L; Hopewell JC; Chen F; Wallendszus K; Stevens W; Collins R; Wiviott SD; Cannon CP; Braunwald E; Sammons E; Landray MJ
N Engl J Med; 2017 Sep; 377(13):1217-1227. PubMed ID: 28847206
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
